Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 13 years
- Director since
- 2023
13 years of board service in total across 4 boards, counting each seat separately. Longest: Agios Pharmaceuticals Inc., 3 years.
Agios Pharmaceuticals Inc.
Director
Denali Therapeutics Inc.
Director
Prime Medicine Inc.
Director
Regeneron Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2026 | Denali Therapeutics Inc. | Grant or award | +6,408 | — | — |
| Jan 2, 2026 | Regeneron Pharmaceuticals Inc. | Grant or award | +155 | — | — |
| Jun 3, 2025 | Denali Therapeutics Inc. | Grant or award | +6,037 | — | — |
| Jan 2, 2025 | Regeneron Pharmaceuticals Inc. | Grant or award | +166 | — | — |
| Nov 11, 2024 | Denali Therapeutics Inc. | Option exercise | +47,165 | $18.00 | $848,970 |
| Nov 11, 2024 | Denali Therapeutics Inc. | Open-market sale | −27,129 | $32.09 | $870,570 |
| Nov 11, 2024 | Denali Therapeutics Inc. | Open-market sale | −32,312 | $32.87 | $1,062,095 |
| Jun 13, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +3,388 | — | — |
| May 31, 2024 | Denali Therapeutics Inc. | Grant or award | +5,967 | — | — |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +11,858 | $31.64 | $375,187 |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −11,858 | $33.60 | $398,429 |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +57,471 | $31.64 | $1,818,382 |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −57,471 | $34.89 | $2,005,163 |
| Feb 26, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +20,411 | $31.64 | $645,804 |
| Feb 26, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −20,411 | $33.19 | $677,441 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.